Clearmind Medicine Files Interim Financials
Ticker: CMND · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1892500
Sentiment: neutral
Topics: financials, interim-report, sec-filing
TL;DR
Clearmind Medicine dropped its Q3 financials on 9/16, check the numbers.
AI Summary
Clearmind Medicine Inc. filed its unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the three and nine months ended July 31, 2024, on September 16, 2024. The company is incorporated in Z4 and its fiscal year ends on October 31.
Why It Matters
This filing provides investors with an update on the company's financial performance and operational status for the period ending July 31, 2024.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain significant new risk factors.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the report
- July 31, 2024 (date) — End of reporting period for financial statements
- September 16, 2024 (date) — Date of filing
- Vancouver, British Columbia (location) — Company's principal executive offices
FAQ
What period do the unaudited condensed interim consolidated financial statements cover?
The financial statements cover the three and nine months ended July 31, 2024.
When were these financial statements filed?
The financial statements were filed on September 16, 2024.
What is Clearmind Medicine Inc.'s fiscal year end?
Clearmind Medicine Inc.'s fiscal year ends on October 31.
Where are Clearmind Medicine Inc.'s principal executive offices located?
The principal executive offices are located at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
Under which form does Clearmind Medicine Inc. file its annual reports?
Clearmind Medicine Inc. files its annual reports under cover of Form 20-F.
Filing Stats: 346 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-09-16 16:01:24
Filing Documents
- ea0213586-6k_clearmind.htm (6-K) — 15KB
- ea021358601ex99-1_clearmind.htm (EX-99.1) — 570KB
- ea021358601ex99-2_clearmind.htm (EX-99.2) — 150KB
- 0001213900-24-078955.txt ( ) — 4478KB
- cmnd-20240731.xsd (EX-101.SCH) — 75KB
- cmnd-20240731_cal.xml (EX-101.CAL) — 38KB
- cmnd-20240731_def.xml (EX-101.DEF) — 254KB
- cmnd-20240731_lab.xml (EX-101.LAB) — 470KB
- cmnd-20240731_pre.xml (EX-101.PRE) — 268KB
- ea0213586-6k_clearmind_htm.xml (XML) — 585KB
Management's Discussion and Analysis for the for the three and nine months ended July 31, 2024
Management's Discussion and Analysis for the for the three and nine months ended July 31, 2024. 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine Inc. Date: September 16, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3